Morris Jeffrey Allen 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Aug 14, 2023
Insider Transaction Report
Form 4
Morris Jeffrey Allen
10% Owner
Transactions
- Award
8% Secured Convertible Promissory Note
2023-08-11→ 244,584 totalExercise: $2.86From: 2023-08-11Exp: 2024-08-11→ Series D-1 Convertible Preferred Stock (244,584 underlying)
Holdings
- 12,000,000
Common Stock
- 6,500,000(indirect: By IRA)
Common Stock
- 3,995,747
Series D-1 Convertible Preferred Stock
Footnotes (5)
- [F1]The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
- [F2]The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
- [F3]The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock.
- [F4]The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
- [F5]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").